Publications

• Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.

  (Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK.) Surgery. 2019 Sep;166(3):277-285.

• Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.

  (Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC.) Ann Surg Oncol. 2019 Aug 15.

• Editorial: Small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors: Observation becoming standard of care?

  (Clarke CN, Evans DB.) Surgery. 2019 Aug;166(2):164-165.

• Distal splenorenal and mesocaval shunting at the time of pancreatectomy.

  (Chavez MI, Tsai S, Clarke CN, Aldakkak M, Griffin MO, Khan AH, Ritch PS, Erickson BA, Evans DB, Christians KK.) Surgery. 2019 Feb;165(2):298-306.

• Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.

  (Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, Campbell BH, Doffek KL, Evans DB, Wang TS.) Thyroid. 2018 11;28(11):1462-1467.

• Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.

  (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2018 Oct 11.

• A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.

  (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2018 10;268(4):610-619.

• A postoperative parathyroid hormone-based algorithm to reduce symptomatic hypocalcemia following completion/total thyroidectomy: A retrospective analysis of 591 patients.

  (Mazotas IG, Yen TWF, Park J, Liu Y, Eastwood DC, Carr AA, Evans DB, Wang TS.) Surgery. 2018 10;164(4):746-753.

• Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations.

  (Zhang J, Jiang J, Luo Y, Li X, Lu Z, Liu Y, Huang J, Hou Y, Pang Y, Sun MYF, Wang TS, Evans DB, Pacak K, Zhuang Z, Gao X.) Endocrine. 2018 08;61(2):216-223.

• What Makes a Pancreatic Cancer Resectable?

  (Evans DB.) Am Soc Clin Oncol Educ Book. 2018 May 23;38:300-305.

• Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions.

  (Bhandari S, Abdul MKM, Hollabaugh W, Sharma K, Evans DB, Guda N.) PLoS One. 2018;13(7):e0199909.

• Pancreatic neuroendocrine tumors

  (Yao JC, Clarke CN, Evans DB.) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 16 November 2018:1353-1367.